Several possible studies
Story checked
Study explores potential breast cancer benefits of neurokinin receptor antagonists (opens in a new tab)
news-medical.net · 2026-10-20
Short answer
Several possible studiesNo confirmed study match.
Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Study explores potential breast cancer benefits of neurokinin receptor antagonists
news-medical.net · 2026-10-20
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Cited as backgroundpresented as the new finding
https://menopause.org/press-releases/researchers-explore-a-potential-role-for-nkr-antagonists-in-breast-cancer-biology
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedNeurokinin receptor antagonists are already widely used for treating menopausal hot flashes, and a new study suggests they may also help breast cancer patients by limiting the spread of cancer cells and helping to prevent a recurring cancer diagnosis.View evidenceHide evidence
As statedwidely used; may also help
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 5Not checkedIn-silico analyses suggested that downregulation of neurokinin receptor signaling suppresses molecular pathways that promote invasiveness and metastatic spread.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 5Not checkedImmunohistochemical analyses showed a linear increase in neurokinin receptor expression from normal to hyperplastic to cancerous breast tissue, suggesting over-expression in cancerous tissue.View evidenceHide evidence
As statedlinear increase
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 5Not checkedIn vitro treatment of human breast cancer cells with neurokinin receptor antagonists reduced cancer cell viability and downregulated oncogenic pathways relevant to cancer progression and resistance to therapeutics.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 5Not checkedThe researchers hypothesize that long-term use of neurokinin receptor antagonist drugs may have therapeutic potential for slowing breast cancer progression and preventing breast cancer recurrence, but these effects must first be substantiated in appropriately designed studies.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref, Europe PMC · 15 candidate papers
Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer.
Breast Cancer Research and Treatment · 2013 · PubMed
CHOOSING WISELY IN PROPHYLACTIC NEUROKININ-1 RECEPTOR ANTAGONIST USE AMONG WOMEN WITH BREAST CANCER: A RETROSPECTIVE COHORT STUDY
Crossref
A Dual-Purpose Approach for an Anti-Emetic NK1R Antagonist as a Chemosensitizer and Cardioprotectant in a Preclinical Model of Triple-Negative Breast Cancer.
International Journal of Molecular Sciences · 2025 · PubMed, Europe PMC
Neurokinin-3 Receptor Antagonist
Definitions · 2020 · Crossref
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications.
2026 · Europe PMC